Incmga00012 (** Not available/Unknown **)

Other Medications

EU Experimental ES Not available 1 Clinical Trials

Description

Incmga00012 is an investigational medication currently being studied in clinical trials. It is being evaluated for its potential use in treating certain advanced solid tumors, including colorectal cancer (CRC). The trials are in the early phase (Phase 1), primarily focused on determining the safe dosage and how the body processes the drug. It is being tested both alone and in combination with another investigational drug called INCB106385. The goal of these early trials is to assess safety and identify potential signs of effectiveness, not to cure the disease. It is important to remember that Incmga00012 is not yet approved for treating CRC or any other condition.

Mechanism of Action

Incmga00012 is being studied in combination with INCB106385. The specific way Incmga00012 works (its mechanism of action) is not fully detailed in the available trial information. However, it is being investigated in combination with INCB106385, which targets a specific protein involved in immune cell function (specifically, INCB106385 targets the protein MDM2). The combination aims to potentially enhance the activity of the immune system against cancer cells. The precise role of Incmga00012 in this combination is still under investigation.

Side Effects

As Incmga00012 is an investigational drug in Phase 1 trials Comprehensive information on side effects is still being gathered. The primary focus of Phase 1 trials is safety. Common side effects observed in early-phase trials can vary widely depending on the dose and individual patient factors. Specific side effects related to Incmga00012 are still being evaluated in ongoing clinical studies. Patients participating in these trials are closely monitored for any adverse events.

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT04580485 Phase 1
Archived
INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors
United States, Belgium, France, Italy, Spain, United Kingdom

Quick Info

Brand Name** Not available/Unknown **
CategoryOther Medications
EU EMA StatusExperimental
ES Spain AccessNot available
Clinical Trials1
View Clinical Trials Back to Drug Glossary

Related Medications

Uracil
Other Medications
771 trials
Leucovorin
Other Medications
631 trials
Trifluridine
Other Medications
45 trials
Paclitaxel
Other Medications
43 trials
Cyclophosphamid
Other Medications
40 trials
Cyclophosphamide
Other Medications
39 trials

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.